Literature DB >> 26423601

Proteoglycans in Leiomyoma and Normal Myometrium: Abundance, Steroid Hormone Control, and Implications for Pathophysiology.

Nichole M Barker1, David A Carrino2, Arnold I Caplan3, William W Hurd4, James H Liu5, Huiqing Tan6, Sam Mesiano7.   

Abstract

Uterine leiomyoma are a common benign pelvic tumors composed of modified smooth muscle cells and a large amount of extracellular matrix (ECM). The proteoglycan composition of the leiomyoma ECM is thought to affect pathophysiology of the disease. To test this hypothesis, we examined the abundance (by immunoblotting) and expression (by quantitative real-time polymerase chain reaction) of the proteoglycans biglycan, decorin, and versican in leiomyoma and normal myometrium and determined whether expression is affected by steroid hormones and menstrual phase. Leiomyoma and normal myometrium were collected from women (n = 17) undergoing hysterectomy or myomectomy. In vitro studies were performed on immortalized leiomyoma (UtLM) and normal myometrial (hTERT-HM) cells with and without exposure to estradiol and progesterone. In leiomyoma tissue, abundance of decorin messenger RNA (mRNA) and protein were 2.6-fold and 1.4-fold lower, respectively, compared with normal myometrium. Abundance of versican mRNA was not different between matched samples, whereas versican protein was increased 1.8-fold in leiomyoma compared with myometrium. Decorin mRNA was 2.4-fold lower in secretory phase leiomyoma compared with proliferative phase tissue. In UtLM cells, progesterone decreased the abundance of decorin mRNA by 1.3-fold. Lower decorin expression in leiomyoma compared with myometrium may contribute to disease growth and progression. As decorin inhibits the activity of specific growth factors, its reduced level in the leiomyoma cell microenvironment may promote cell proliferation and ECM deposition. Our data suggest that decorin expression in leiomyoma is inhibited by progesterone, which may be a mechanism by which the ovarian steroids affect leiomyoma growth and disease progression.
© The Author(s) 2015.

Entities:  

Keywords:  leiomyoma; proteoglycans; steroid hormones

Mesh:

Substances:

Year:  2015        PMID: 26423601      PMCID: PMC5933092          DOI: 10.1177/1933719115607994

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  40 in total

1.  Progesterone and progesterone receptor modulator in uterine leiomyoma growth.

Authors:  Takeshi Maruo
Journal:  Gynecol Endocrinol       Date:  2007-04       Impact factor: 2.260

2.  Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta.

Authors:  B S Lee; R A Nowak
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.

Authors:  Lynnette K Nieman; Wendy Blocker; Tonja Nansel; Sheila Mahoney; James Reynolds; Diana Blithe; Robert Wesley; Alicia Armstrong
Journal:  Fertil Steril       Date:  2010-11-05       Impact factor: 7.329

4.  Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women.

Authors:  Minnie Malik; John Norian; Desirée McCarthy-Keith; Joy Britten; William H Catherino
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

5.  A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.

Authors:  Jiayin Wang; Noriyuki Ohara; Zhuo Wang; Wei Chen; Akira Morikawa; Hiroko Sasaki; Deborah A DeManno; Kristof Chwalisz; Takeshi Maruo
Journal:  Hum Reprod       Date:  2006-04-13       Impact factor: 6.918

6.  Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle.

Authors:  E A Stewart; A J Friedman; K Peck; R A Nowak
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

7.  Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics.

Authors:  Sara A Carney; Hidetoshi Tahara; Carol D Swartz; John I Risinger; Hong He; Alicia B Moore; Joseph K Haseman; J Carl Barrett; Darlene Dixon
Journal:  Lab Invest       Date:  2002-06       Impact factor: 5.662

Review 8.  Treatment strategies for uterine leiomyoma: the role of hormonal modulation.

Authors:  Jennifer D Cook; Cheryl Lyn Walker
Journal:  Semin Reprod Med       Date:  2004-05       Impact factor: 1.303

9.  Estradiol induces transcriptional and posttranscriptional modifications in versican expression in the mouse uterus.

Authors:  Renato M Salgado; Ambart C Covarrubias; Rodolfo R Favaro; Caroline Serrano-Nascimento; Maria Tereza Nunes; Telma M T Zorn
Journal:  J Mol Histol       Date:  2012-12-28       Impact factor: 2.611

Review 10.  Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.

Authors:  Nicoletta Biglia; Silvestro Carinelli; Antonio Maiorana; Marta D'Alonzo; Giuseppe Lo Monte; Roberto Marci
Journal:  Drug Des Devel Ther       Date:  2014-02-20       Impact factor: 4.162

View more
  6 in total

Review 1.  Recent Advances in Uterine Fibroid Etiology.

Authors:  Michelle M McWilliams; Vargheese M Chennathukuzhi
Journal:  Semin Reprod Med       Date:  2017-03-09       Impact factor: 1.303

2.  Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.

Authors:  Jeris Cox; Minnie Malik; Joy Britten; Terrence Lewis; William H Catherino
Journal:  Reprod Sci       Date:  2017-09-20       Impact factor: 3.060

3.  Versican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma.

Authors:  Ndeye-Aicha Gueye; Timothy J Mead; Christopher D Koch; Charles V Biscotti; Tommaso Falcone; Suneel S Apte
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

Review 4.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

5.  Evidence of biomechanical and collagen heterogeneity in uterine fibroids.

Authors:  Friederike L Jayes; Betty Liu; Liping Feng; Nydea Aviles-Espinoza; Sergey Leikin; Phyllis C Leppert
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

6.  Preliminary Application of Magnetization Transfer Imaging in the Study of Normal Uterus and Uterine Lesions.

Authors:  Qiu Bi; Qing Li; Jing Yang; Junyu Yang; Ji Du; Fan Ding; Yunzhu Wu; Shaoyu Wang; Ying Zhao
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.